Printer Friendly

/C O R R E C T I O N -- CEL-SCI CORPORATION/

 In DC002, CEL-SCI Corporation Responds to Broker Inquiries Regarding Trading Activity in CEL-SCI Shares, moved Wednesday, Sept. 1, the second graph, third line, should read "estimating Multikine(TM) to generate revenues," rather than "estimating that Multikine(TM) to generate revenues," as originally transmitted. Also, the third graph, second line, should read "cytokine mixture (Multikine)," rather than "cytokine mixtures," as originally transmitted. The full corrected text of the release follows:
 CEL-SCI CORPORATION RESPONDS TO BROKER INQUIRIES
 REGARDING TRADING ACTIVITY IN CEL-SCI SHARES
 ALEXANDRIA, Va., Sept. 1 /PRNewswire/ -- In response to numerous inquiries from brokers and investors regarding trading activity in its common stock yesterday, CEL-SCI Corporation (NASDAQ-NMS: CELI) said that it believes the activity to have been the result of the issuance of a research report recommending accumulation of CEL-SCI shares. The company knows of no other news which would account for yesterday's activity.
 The research report was prepared and issued by Cohig & Associates' analyst Douglas J. Fahoury. In the report, Fahoury states: "We are estimating Multikine(TM) to generate revenues of approximately $130 million in 1997, increasing to $424 million in 1999. Discounting the 1997 revenues at a factor of 25 percent per year would equal $53 million. Using a biotech industry average multiple of four times annual revenues, Multikine could be valued at $223 million, or $5.46 per share. Discounting 1999 revenues gives CELI a potential value of $455 million, or $11 per share. If CELI's AIDS vaccine proves viable, the potential value of CELI could be significantly higher."
 CEL-SCI Corporation has pioneered the development of a natural cytokine mixture (Multikine) for the treatment of cancers and other immunodeficiency diseases. Its 50 percent owned subsidiary, Viral Technologies, Inc., is developing the HGP-30 AIDS vaccine, based upon a highly conserved segment of the p17 "core" protein of the AIDS virus.
 -0- 9/2/93
 /CONTACT: Matthew Haines, director of investor relations, CEL-SCI Corporation, 212-996-0608/
 (CELI)


CO: CEL-SCI Corporation ST: Virginia IN: MTC SU:

KD-DC -- DC100 -- 8370 09/02/93 11:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 2, 1993
Words:333
Previous Article:AIRBUS INDUSTRIE REPUDIATES MAGAZINE SURVEY, CHARGES WIRE SERVICE STORY IRRESPONSIBLE
Next Article:FUEL-TECH N.V. TO TRADE ON NASDAQ
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters